Harrow Health is trading at $26.50, down 7.15% versus the November 3 close, with no clear company-specific announcement explaining the November 4 pre-market decline in available coverage.
- Harrow’s next earnings report is scheduled for November 9, not November 4.
- Pre-market healthcare and broad U.S. futures are higher, but neither trend explains Harrow’s opposite-direction move.
- No reliable trading-volume figure was available.